![](/fileadmin/_processed_/csm_Decoy_cell_cytology_f1d4d78e91.png)
Memo Therapeutics AG increases Series C financing to CHF45m
New investors Ysios Capital and Kurma Partners joined existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_Neuroblastom_Primary_super_close_merged_cfdf8283a7_47aac544fd.jpg)
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
![](/fileadmin/_processed_/csm_puppy-1207816_1280_b8d31894a0.jpg)
First dog snack from microbial protein
Single cell protein specialist MicroHarvest GmbH is set to co-develop the very first pet feed reducing the carbon dioxide pawprint of dogs in...
![](/fileadmin/_processed_/csm_Fundus_of_patient_with_retinitis_pigmentosa__mid_stage_10790b28cb.jpg)
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Fundus_-_diabetic_retinopathy_c83d88301e.png)
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
With the strategic acquisition,which has been unanimously approved by the EyeBio Board of Directors, MSD will take over Eyebiotech's clinical...